BioCentury
ARTICLE | Company News

MacroGenics, Synthon deal

December 16, 2016 8:28 PM UTC

Synthon granted MacroGenics rights to duocarmycin-based linker-drug technology to develop and commercialize preclinical MGC018. Synthon will receive license fees and is eligible for milestones and roy...

BCIQ Company Profiles

MacroGenics Inc.

Synthon B.V.

BCIQ Target Profiles

B7-H3 (CD276)